Astellas Email Format
Pharmaceutical Manufacturing
・
10,001+ employees
・
Tokyo, Japan
Astellas is a global pharmaceutical company that develops and delivers transformative therapies in oncology, ophthalmology, urology, immunology, and women's health to patients worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@astellas.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2005
Headquarters
Tokyo, Japan
Revenue
$500M-$1B
FUNDING Stage
Public
Website
Key Executives
Naoki Okamura (Representative Director, President and Chief Executive Officer (CEO)), Atsushi Kitamura (Chief Financial Officer (CFO)), Claus Zieler (Chief Commercial & Medical Affairs Officer (CCMAO))
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Astellas?
Astellas uses the first.last format, so Jane Smith would be jane.smith@astellas.com.
What therapeutic areas does Astellas focus on?
Astellas focuses on oncology, ophthalmology, urology, immunology, and women's health. Its current portfolio includes strategic brands such as PADCEV for urothelial cancer, XTANDI for prostate cancer, IZERVAY for geographic atrophy, and VEOZAH for menopausal vasomotor symptoms.
Who leads Astellas as CEO in 2026?
Naoki Okamura serves as Representative Director, President and Chief Executive Officer of Astellas in 2026, with Atsushi Kitamura as CFO and Claus Zieler as Chief Commercial and Medical Affairs Officer.
Where is Astellas headquartered and how many employees does it have?
Astellas is headquartered in Tokyo, Japan, and employs approximately 12,349 people. Tools like Clay can help you find and verify specific Astellas contacts by role or region for outreach purposes.
How does Astellas use immuno-oncology and targeted protein degradation in its research strategy?
Astellas has identified immuno-oncology and targeted protein degradation as primary focus areas within its R&D strategy, alongside cell and gene therapy, as part of its 2026 Corporate Strategic Plan aimed at expanding its oncology pipeline beyond existing approved medicines.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating